CIK 0001604464
- Non-accelerated filer
- Smaller reporting company
Atara Biotherapeutics, Inc.
Sign in to watch- Ticker
- ATRA
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 460920988
- Phone
- +1 805-623-4211
- Business address
- 1280 RANCHO CONEJO BLVD, THOUSAND OAKS, CA, 91320
- 4 Open-market sale President and CEO sold 8,223 shares at $12.53 ($103,051)
- 4 Open-market sale Chief Operations Officer sold 2,426 shares at $12.53 ($30,403)
- 4 Open-market sale SVP, GC & Secretary sold 2,080 shares at $12.53 ($26,067)
- 4 Open-market sale Chief Financial Officer sold 3,579 shares at $12.53 ($44,852)
- 4 Open-market sale EVP, Head of R&D sold 2,152 shares at $12.53 ($26,969)
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Open-market sale President and CEO sold 14,194 shares at $16.32 ($231,660)
- 4 Open-market buy Chief Commercial Officer bought 34,354 shares at an average $14.57 ($500,370)
- 4 Grant or award Director acquired 11,000 shares (grant or award)
- 4 Grant or award Director acquired 11,000 shares (grant or award)
- 4 Grant or award Director acquired 11,000 shares (grant or award)
- 4 Grant or award Director acquired 11,000 shares (grant or award)
- 4 Grant or award Director acquired 11,000 shares (grant or award)
- 4 Grant or award Director acquired 11,000 shares (grant or award)
- 4 Grant or award Director acquired 11,000 shares (grant or award)
- 4 Grant or award Director acquired 11,000 shares (grant or award)
- 4 Open-market sale Chief Financial Officer sold 5,820 shares at $14.06 ($81,829)
- 4 Open-market sale Chief Operations Officer sold 2,453 shares at $14.55 ($35,691)
- 4 Open-market sale EVP, Head of R&D sold 5,184 shares at $14.55 ($75,427)
Page 9 of 33 · 644 filings